Purchase of pharmaceuticals which treat the underlying cause of cystic fibrosis (CFTR modulators)

Hange

15 - Voluntary ex ante transparency notice
Eelteade
04.10.2018 10:18 (GMT+03:00)

Hankija

Amgros I/S Amgros I/S
Jon Bjergfelt Jon Bjergfelt
Dampfærgevej 22
2100 København Ø
Taani

Eesmärk

Cystic fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is caused by the presence of mutations in both copies of the gene for the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) protein. Today, patients with cystic fibrosis are mainly treated with pharmaceuticals which reduce the symptoms of cystic fibrosis without treating their underlying cause. Amgros wishes to enter into a contract ensuring that public hospitals in Denmark, Greenland and the Faroe Islands will be able to offer all their cystic fibrosis patients treatment with pharmaceuticals, which treat the underlying cause of cystic fibrosis (CFTR modulators).

Mercell Estonia OÜ

Mercelli gruppi kuuluv Euroopa juhtiv e-hanke keskkond vahendab infot ostjate ja tarnijate vahel.

Kontakt

Mercell Eesti kasutajatugi

+372 683 6785
Mercell Estonia OÜ | Põhja puiestee 21C, 10143 Tallinn, Eesti